Growth Metrics

Heron Therapeutics (HRTX) Income from Continuing Operations (2016 - 2026)

Heron Therapeutics filings provide 15 years of Income from Continuing Operations readings, the most recent being 4765000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations fell 251.08% to 4765000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 10457000.0, a 192.42% decrease, with the full-year FY2025 number at 10195000.0, up 27.23% from a year prior.
  • Income from Continuing Operations hit 4765000.0 in Q1 2026 for Heron Therapeutics, down from 38000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 4173000.0 in Q4 2024 to a low of 62923000.0 in Q1 2022.
  • Median Income from Continuing Operations over the past 5 years was 6445000.0 (2024), compared with a mean of 17888470.59.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 165.74% in 2025 and later crashed 251.08% in 2026.
  • Heron Therapeutics' Income from Continuing Operations stood at 20355000.0 in 2022, then skyrocketed by 49.79% to 10220000.0 in 2023, then surged by 140.83% to 4173000.0 in 2024, then crashed by 99.09% to 38000.0 in 2025, then plummeted by 12639.47% to 4765000.0 in 2026.
  • The last three reported values for Income from Continuing Operations were 4765000.0 (Q1 2026), 38000.0 (Q4 2025), and 4093000.0 (Q3 2025) per Business Quant data.